GSK461364 is an ATP-competitive inhibitor of Plk1 and forms a rapidly reversible complex with Plk1. It has a 400-fold greater potency for Plk1 than for Plk2 and Plk3. In vitro, this compound showed antiproliferative activity in >120 cancer cell lines tested. GSK461364 demonstrated tumor growth inhibition in animal models. In these xenograft models, GSK461364 showed antitumor activity ranging from complete tumor growth inhibition to growth delay. Interestingly, the compound caused dose-dependent mitotic arrest in Colo205 xenografts in vivo.
|Source||Int J Oncol (2016). Figure 1. GSK461364|
|Cell Lines||U2OS cells|
|Concentrations||0.5, 1, 2 μM|
|Incubation Time||24 h|
|Results||OS cells were treated with GSK461364 and the levels of PLK1 and pCDC25C (a downstream effector of PLK1) were measured through western blotting. Except for U2OS in time-dependent studies, decreased level of PLK1 and pCDC25C were noted in all three GSK461364-treated OS cell lines|
|Cell lines||MDA-MB-231, A549, and PC3 cell line|
|Preparation method||Cell lines were obtained from American Type Culture Collection and grown in the recommended media at 37°C, 5% CO2 in a humidified incubator. Cells were plated in triplicate 96-well microtiter plates at 1,000 cells per well in culture media. GSK461364A dissolved in DMSO or negative control (0.1% DMSO) were added the following day, and one plate was harvested with 50 μL of CellTiter-Glo (Promega) for a time 0 (T = 0) measurement. Remaining duplicate cell plates were typically incubated for 72 h. Cells were then lysed with 50 μL CellTiter-Glo, and chemiluminescent signal was read on the Wallac EnVision 2100 plate reader. All data were normalized to signal at time of compound addition (T = 0). Curves were analyzed using the XLfit (IDBS Ltd.) curve-fitting tool for Microsoft Excel to determine the gI50 (concentration of 50% growth inhibition relative to T = 0 and Ymax values), the gI-maximum (concentration giving maximum growth inhibition), and the Ymin (bottom of the four-parameter curve at gI-maximum).|
|Incubation time||72 h|
|Animal models||mice bearing Colo205 tumor xenograft model|
|Formulation||4% DMA/Cremaphore (50:50), pH 5.6|
|Dosages||every 2 d (q2dx6, q2dx12) or every 4 d (q4dx3) at nominal dose levels of 25, 50, and 100 mg/kg/dose|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).
Liu-Sullivan et al. Oncotarget. 2011 Dec;2(12):1254-64. PMID: 22248814.
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos et al. Clin Cancer Res. 2011 May 15;17(10):3420-30. PMID: 21459796.
Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG, et al. Cancer Res. 2009 Sep 1;69(17):6969-77. PMID: 19690138.
|Related PLK Products|
ON1231320, also known as GBO-006, is a Polo-like kinase 2 (PLK2) inhibitor. In vitro testing revealed that ON1231320 is a selective inhibitor of PLK2 with no inhibitory activity against PLK1, PLK3 and PLK4.
HMN-214 is a procompound of HMN-176, which alters the cellular spatial orientation of Plk1.
TAK-960 is a novel, potent and selective Plk1 inhibitor with IC50 of 8 nM.
RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.